Physician profile
Brittni Usera
NPI 1497259337
$1,317.89
in general payments reported to CMS, 2019-2025
27 companies · $811 in 2025
The $811 reported for 2025 was more than what 81% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $338 · 2024: $169 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $151.00 | 2025 | |
| Accuray Incorporated | $131.98 | 2023 | Cyberknife System |
| Brainlab, INC. | $122.91 | 2023 | Image Guided Surgical Device |
| Novocure INC. | $95.59 | 2023-2025 | Optune, Optune Gio |
| Janssen Biotech, INC. | $95.35 | 2024-2025 | Rybrevant, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $87.68 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $54.39 | 2025 | Libtayo |
| Sobi, INC | $49.97 | 2024-2025 | |
| Tersera Therapeutics LLC | $47.71 | 2025 | Xermelo, Zoladex |
| Takeda Pharmaceuticals U.S.A., INC. | $46.12 | 2024-2025 | Iclusig, Vpriv |
| Astellas Pharma US INC | $38.72 | 2025 | Vyloy |
| Ipsen Biopharmaceuticals, INC | $38.13 | 2025 | Onivyde |
| Astrazeneca Pharmaceuticals LP | $36.79 | 2025 | Lynparza |
| Gilead Sciences, INC. | $34.63 | 2024 | Trodelvy |
| Kyowa Kirin, INC. | $29.32 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $27.87 | 2025 | |
| Coherus Oncology, INC. | $27.37 | 2025 | Loqtorzi |
| Incyte Corporation | $25.47 | 2025 | Jakafi |
| Tactile Systems Technology INC | $24.97 | 2025 | Flexitouch Plus, Nimbl |
| Puma Biotechnology, INC. | $23.92 | 2025 | |
| Eisai INC. | $23.45 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.44 | 2025 | |
| Blueprint Medicines Corporation | $18.88 | 2025 | Ayvakit |
| Abbvie INC. | $16.46 | 2023 | Teflaro, Avycaz, Dalvance |
| Emd Serono, INC. | $16.24 | 2025 | |
| Apellis Pharmaceuticals, INC. | $15.40 | 2025 | Empaveli |
| Bayer Healthcare Pharmaceuticals INC. | $15.13 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittni Usera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.